Tuesday, May 08, 2018 8:04:18 AM
Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.
Where is the 60percent premium to Close of March 27 2018 at shire 128.87
Never Never buy/sell any security based on my post(s). I DO NOT receive any compensation in any form (cash or shares) from any company or 3rd party mentioned in my post(s). All my posts are my OPINION only.
ALWAYS CHECK WITH A FINANCIAL ADVISER
Recent TAK News
- Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire... • Business Wire • 05/10/2024 11:03:00 AM
- Takeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023, liefert Ausblick auf das GJ 2024, und bekräftigt Bekenntnis zur Pipeline-Entwicklung in der späten Entwicklungsphase sowie zur Steigerung der operativen Gewinnmarge • Business Wire • 05/09/2024 09:07:00 PM
- Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion • Business Wire • 05/09/2024 06:07:00 AM
- 2023年度通期業績および2024年度の見通しを公表 - 後期段階のパイプライン開発とCore営業利益率改善へのコミットメントを強調 • Business Wire • 05/09/2024 06:07:00 AM
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer • Business Wire • 04/26/2024 12:30:00 PM
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder • PR Newswire (US) • 04/23/2024 11:00:00 AM
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs • PR Newswire (US) • 04/22/2024 08:10:00 AM
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease • Business Wire • 04/18/2024 11:00:00 PM
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food • Business Wire • 04/08/2024 12:00:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:56:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:53:00 PM
- Takeda annonce les candidats au conseil d’administration pour la prochaine assemblée générale des actionnaires • Business Wire • 03/27/2024 05:01:00 AM
- Takeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekannt • Business Wire • 03/27/2024 05:01:00 AM
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting • Business Wire • 03/26/2024 11:07:00 PM
- 第148回定時株主総会に提案する取締役候補者について • Business Wire • 03/26/2024 11:07:00 PM
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) • Business Wire • 03/26/2024 12:00:00 PM
- 武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®(ポナチニブ)の医薬品承認事項変更申請(sNDA)について、FDAからの承認取得を発表 • Business Wire • 03/21/2024 01:39:00 PM
- Takeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch die FDA bei erwachsenen Patienten mit neu diagnostizierter Ph+ ALL • Business Wire • 03/21/2024 07:33:00 AM
- Takeda annonce l'approbation par la FDA des États-Unis d'une demande supplémentaire de nouveau médicament (sNDA) pour ICLUSIG ® (ponatinib) chez les patients adultes atteints de leucémie lymphoblastique aiguë (LAL Ph+) nouvellement diagnostiquée • Business Wire • 03/20/2024 07:18:00 PM
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL • Business Wire • 03/19/2024 04:20:00 PM
- CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders • GlobeNewswire Inc. • 03/19/2024 10:30:54 AM
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia • Business Wire • 03/13/2024 12:00:00 PM
- 武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力 • Business Wire • 02/28/2024 12:03:00 PM
- Takeda et Biological E. Limited s’associent pour accélérer l’accès au vaccin contre la dengue dans les zones endémiques • Business Wire • 02/27/2024 10:26:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM